Valvular & structural heart disease
Association of ACEI/ARB and statin prescribing patterns with mortality after Transcatheter Aortic Valve Replacement (TAVR): Findings from real-world claims data
Authors' conclusion
In this large-scale, real-world analysis of patients undergoing TAVR, the prescription of ACEI/ARB and statins was associated with a significantly lower risk of mortality at 3-years, especially in those where the medications were initiated preoperatively.
Study context
- Population
- Adults who received TAVR for aortic stenosis (AS), Optum claims data, January 2014–December 2018
- Participants
- 9,012 adults
- Exposure
- ACEi/ARB or statin prescription vs no prescription after TAVR
- Outcome
- All-cause mortality
- Follow-up
- 3 years
Methodological detailsclaims data, 90-day landmark, adjusted Cox models
- Claims data
- 90-day landmark
- Adjusted Cox models
Main finding
As reported in the abstract
Adjusted mortality
Each group vs no prescriptionHazard ratio (95% CI)P value
ACEI/ARB
0.82(0.74–0.91)
P = 0.0003Statin
0.85(0.77–0.94)
P = 0.0018Observational data: associations, not effects.
Further findings
Mortality, subgroups (11 potential confounders)
- Preoperative ACEI/ARB prescription associated with significantly lower mortality risk vs postoperative prescription only
- No other subgroup variables had significant interactions, including preoperative statin use
Original publication
Association of ACEI/ARB and statin prescribing patterns with mortality after Transcatheter Aortic Valve Replacement (TAVR): Findings from real-world claims data. Am Heart J. Published 31 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →